Metallotexaphyrins as MRI-Active Catalytic Antioxidants for Neurodegenerative Disease: A Study on Alzheimer’s Disease
Name
1-s2.0-S2451929419305637-main.pdf
Description
Published version
Size
2.58 MB
Format
Adobe PDF
Checksum (MD5)
e08ceba82523d29d51150e7ba8776132
Author(s)
Brewster, James T.
Thiabaud, Gregory D.
Harvey, Peter
Zafar, Hadiqa
Reuther, James F.
Dell’Acqua, Simone
Johnson, Rachel M.
Root, Harrison D.
Metola, Pedro
Jasanoff, Alan Pradip
Date Issued
March 2020
Journal
Chem
Publisher
Elsevier BV
Citation
Brewster, James T. et al. "Metallotexaphyrins as MRI-Active Catalytic Antioxidants for Neurodegenerative Disease: A Study on Alzheimer’s Disease." Chem 6, 3 (March 2020): P703-724 © 2019 The Author(s)
Version
Final published version
Abstract
The complex etiology of neurodegeneration continues to stifle efforts to develop effective therapeutics. New agents elucidating key pathways causing neurodegeneration might serve to increase our understanding and potentially lead to improved treatments. Here, we demonstrate that a water-soluble manganese(II) texaphyrin (MMn) is a suitable magnetic resonance imaging (MRI) contrast agent for detecting larger amyloid beta constructs. The imaging potential of MMn was inferred on the basis of in vitro studies and in vivo detection in Alzheimer's disease C. elegans models via MRI and ICP-MS. In vitro antioxidant- and cellular-based assays provide support for the notion that this porphyrin analog shows promise as a therapeutic agent able to mitigate the oxidative and nitrative toxic effects considered causal in neurodegeneration. The present report marks the first elaboration of an MRI-active metalloantioxidant that confers diagnostic and therapeutic benefit in Alzheimer's disease models without conjugation of a radioisotope, targeting moiety, or therapeutic payload. Neurodegenerative disease is correlated with aberrant oxidation and nitration of small-molecule neurotransmitters, proteins, DNA, and cellular membrane components. Cellular damage enhanced by these modifications propagates disease progression, leading to death. Effective tools that enable insight into the complex etiology of CNS diseases could allow researchers to find a cure. Part of this effort is focused on developing imaging modalities that can assist in understanding these diseases. Here, we demonstrate a new theranostic strategy that shows promise in addressing the oxidative and nitrative malfunctions considered causal in disease progression. The approach detailed in this report also allows the MRI of aggregated Aβ, which could lead to improvements in disease diagnosis. The present work is thus expected to set the stage for the mechanistic-based design of theranostics, useful in understanding and treating neurodegeneration. Sessler et al. have studied manganese(II) texaphyrin as a catalytic metalloantioxidant theranostic agent for the detection of Aβ aggregates. A series of in vitro and in vivo analyses allowed for the inference that metallotexaphyrins could be used for MRI-based detection of Aβ biomarkers. In vitro and cellular-based assays coupled with mechanistic analysis demonstrated an efficacious protective effect against oxidative and nitrative damage. The present results could thus guide future efforts in developing new theranostic modalities for use in neurodegenerative disease.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution 4.0 International license
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.chempr.2019.12.016
